Competitive Positioning
Enquiry IconContact Us

Market Leaders - Vaccines Industry

Feb, 2023 - By CMI

Market Leaders - Vaccines Industry

Vaccines expose the body to a very little number of weakened or dead viruses or bacteria, which is completely safe. If the body is later exposed to the virus, the immune system will detect it and attack it. The rising frequency of numerous infectious illnesses, as well as the increasing number of vaccine approvals by regulatory agencies, are likely to drive the worldwide vaccines market throughout the forecast period. Moreover, rising adoption of inorganic methods such as partnerships and collaborations by industry major players is likely to help in the expansion of the global vaccines market over the forecast period. Pfizer Inc., a pharmaceutical and biotechnology company, announced in June 2021 that the PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) received FDA approval for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults aged 18 years and older. The high cost of vaccine research and tight government requirements for product clearance are projected to be the primary factors impeding the growth of the global vaccines industry.

According to Coherent Market Insights, the global Vaccines Market is estimated to be valued at US$ 38,305.2 million in 2021 and is expected to exhibit a CAGR of 6.8% during the forecast period (2021-2028).

Key Companies in the vaccines Industry:

1. AstraZeneca GmbH

AstraZeneca PLC was incorporated in 1992.The company is headquartered in Cambridge, the United Kingdom and operational in more than 100 countries. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. In December, 2022 AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL)

2. GlaxoSmithKline plc

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GSK plc and Wave Life Sciences Ltd in December, 2022 announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing programme targeting alpha-1 antitrypsin deficiency (AATD), WVE-006.

3. Pfizer Inc.

Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide. In December, 2022 announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age.

4. Sanofi S.A.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions and was founded in 1973. The company is headquartered in Paris, France and is operational in 100 plus countries. Sanofi and Innate Pharma SA announced in December, 2022 an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.

5. Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.  Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

6. Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. On October 2022, The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer

7. Daiichi Sankyo Co.

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan

8. Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company was founded in 1887 and is headquartered in New York, New York.

9. CSL Limited

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.  On Oct. 5, 2022 CSL announced results from the preclinical studies of the company's self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates, the next generation of mRNA vaccines. The data, published in Molecular Therapy – Methods and Clinical Development, indicate that the sa-mRNA influenza vaccine candidates produced a potent, cross-reactive immune response against pandemic and seasonal influenza strains, A(H5N1) and A(H1N1).1 

10. Serum Institute of India Pvt. Ltd.

Serum Institute of India Pvt, Ltd. is the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses), supplying the world's least expensive and WHO-accredited vaccines to as many as 170 countries. It was founded in 1966, headquartered in Pune, India. On March 23, 2022 Novavax, Inc. and Serum Institute of India Pvt. Ltd. announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' protein-based COVID-19 vaccine for adolescents aged ≥12 to <18 years in India. The vaccine, also known as NVX-CoV2373, is manufactured and marketed in India by SII under the brand name Covovax™ and is the first protein-based vaccine authorized for use in this age group in India.

*Definition - Vaccines serve to build the immune system and protect it from potentially fatal infections such as hepatitis, polio, and TB. Vaccines aid the body's defense against diseases such as viruses and bacteria.

Subscribe Newsletter

Kindly subscribe for our latest news & articles.